Changchun High-Tech Industry (000661.SZ): The application for clinical trials of GenSci136 for injection produced domestically has been approved.

Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Gold Sais Pharmaceutical Co., Ltd. (referred to as "Gold Sais Pharmaceutical"), recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the registration of injectable GenSci136 produced domestically by Gold Sais Pharmaceutical has been approved. Injectable GenSci136 is a dual-target antagonist of BAFF/APRIL independently developed by Gold Sais Pharmaceutical. The Chinese registration category is Class 1 therapeutic biological products, and it is intended to be used for the treatment of ocular myasthenia gravis (oMG).